Game-changing uPAR-targeting dye for guiding surgical treatment of cancer

Project description

Surgical visualisation solution sheds light on brain cancer

Surgery is most commonly used to remove cancer tumours. FluoGuide’s leading product – FG001 – is injected into the patient’s veins prior to surgery. It contains a fluorophore that binds to cancer cells expressing uPAR (highly expressed in virtually all human cancers). FluoGuide’s proprietary FG001 will revolutionise cancer surgery to improve the surgical outcome of more than 3 million cancer patients undergoing treatment every year. Glioblastoma multiforme (GBM) is the most aggressive type of cancer that begins within the brain, with a very poor prognosis. Surgery is currently extremely challenging as removing too much brain tissue can severely disable the patient. The EU-funded INSTAGLOW project will focus on accelerating the development of FG001 for GBM, enormously improving surgery for those patients.

Objective

Surgery is a cornerstone in treatment of early cancer, used in 45% of all patients, although cancer commonly recurs after surgery due to incomplete removal. The residual tumour not only leads to avoidable suffering and even dying of patients but also presents a huge financial burden for the healthcare system. As such, there is a major unmet need to accurately delineate tumour from healthy tissue, identify local metastases, and aid surgeons to precisely remove the entire tumour. FluoGuide will deliver FG001, a breakthrough, real-time, surgical visualisation solution that lights up cancer and improve surgical precision during removal surgery. FG001 is the first active targeting fluorescent tumour marker that targets uPAR, a receptor extensively expressed (95%) in a wide range (>50%) of solid tumours such as brain (glioblastoma; GBM), breast, colorectal, lung and head and neck cancers. FluoGuide’s proprietary FG001 will revolutionise cancer surgery to improve the surgical outcome of >3 million cancer patients undergoing surgery every year.

To realise this huge potential, FluoGuide is working on accelerating the development of FG001. Our initial focus is on GBM for which the prognosis is extremely poor with half of all patients dying within 14 months. Moreover, surgery is extremely challenging as removing too much brain tissue can severely disable the patient. FG001 can thus enormously improve surgery of GBM patients. The funding from EIC accelerator pilot will accelerate FG001’s clinical phase IIb/III study for GBM, and catapult FluoGuide to become a leader in cancer surgery guidance. We will generate revenues by 1) direct sales for compassionate use sales (2021) to showcase FG001, 2) direct sales in EU (2023), paid for via reimbursement by insurance companies and governments, and 3) roll-out to US and Asia (2025) through deals with large regional medical companies for local regulatory approval, and marketing and sales to ensure its full economic potential.

Fields of science

Keywords

Programme(s)

Topic(s)

EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-EIC-SMEInst-2018-2020-3

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

FLUOGUIDE AS

Net EU contribution

€ 2 499 868,69

Address

Ole maaloes vej 3
2200 Copenhagen
Denmark

Region

Danmark Hovedstaden Byen København

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Contact the organisation

Participation in EU R&I programmes

HORIZON collaboration network

Other funding

€ 2 585 381,81